On Wednesday, Galena Biopharma Inc (NASDAQ:GALE)’s shares declined -2.76% to $1.41.
Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care stated its financial results for the quarter ended June 30, 2015 and offered a business update.
FINANCIAL HIGHLIGHTS AND GUIDANCE
Operating loss for the second quarter of 2015 was $11.3 million, counting $0.6 million in stock based compensation, contrast to an operating loss of $15.8 million, counting $1.5 million in stock-based compensation for the same period last year. Operating loss for the first half of 2015 was $22.4 million, counting $1.3 million in stock based compensation, contrast to an operating loss of $27.6 million, counting $3.2 million in stock-based compensation for the same period in 2014. The decrease in net operating loss year-over-year is primarily the result of the completion of enrollment in our Phase 3 PRESENT trial for NeuVax, in addition to the decrease in stock based compensation and professional fees associated with ongoing legal proceedings.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
Sunstone Hotel Investors Inc (NYSE:SHO)’s shares dropped -1.69% to $14.55.
Sunstone Hotel Investors, Inc. (SHO) declared results for the second quarter ended June 30, 2015.
Second Quarter 2015 Operational Results (as contrast to Second Quarter 2014):
- Comparable Hotel RevPAR, counting adoption of the industry’s Uniform System of Accounts for the Lodging Industry, Eleventh Revised Edition (“USALI Eleventh Revised Edition”), which became effective January 1, 2015, raised 7.1% to $184.05.
- Comparable Hotel Adjusted EBITDA Margin, counting USALI Eleventh Revised Edition adoption and not taking into account non-current year property taxes, net raised 160 basis points to 34.9%.
- Adjusted EBITDA raised 16.9% to $110.4 million.
- Adjusted FFO attributable to common stockholders per diluted share raised 10.3% to $0.43.
- Income attributable to common stockholders raised 23.5% to $48.9 million.
- Income attributable to common stockholders per diluted share raised 4.5% to $0.23.
Sunstone Hotel Investors, Inc. operates as a real estate investment trust. The firm engages in the acquisition, ownership, asset administration, renovation, and sale of luxury, upper upscale, and upscale full-service hotels in the United States. Its portfolio also comprises mid-scale hotels. Sunstone Hotel Investors was founded in 1995 and is based in Aliso Viejo, California.
At the end of Wednesday’s trade, KLA-Tencor Corp (NASDAQ:KLAC)‘s shares dipped -0.36% to $50.01.
KLA-Tencor Corporation (KLAC), the world’s leading supplier of process control and yield administration solutions for the semiconductor and related nanoelectronics industries, declared that its board of directors has authorized an enhance in the level of the company’s quarterly dividend from $0.50 to $0.52 per share. This enhance is predictable to take effect starting with KLA-Tencor’s quarterly dividend to be declared in August 2015. This represents a four percent enhance contrast to the preceding quarterly dividend, and is the seventh quarterly dividend enhance since KLA-Tencor first instituted its dividend policy in April 2005. In addition to its regular quarterly dividend, KLA-Tencor also paid a special dividend of $16.50 per share in December of 2014.
KLA-Tencor Corporation designs, manufactures, and markets process control and yield administration solutions worldwide. It provides chip manufacturing products, counting front-end defect inspection, back-end defect inspection, defect review, metrology, and in-situ process monitoring products, in addition to lithography modeling software; wafer manufacturing products comprising surface and defect inspection, wafer geometry and nanotopography metrology, and data administration; and reticle manufacturing products, such as defect inspection
Advaxis, Inc. (NASDAQ:ADXS), ended its Wednesday’s trading session with -7.46% loss, and closed at $14.89.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, declared that it has designated Shelonitda S. Rose, M.D., as Vice President, Clinical Development. Dr. Rose brings to Advaxis more than 15 years of experience in medical oncology and hematology clinical research.
In her role as Vice President, Clinical Development, Dr. Rose will report to Advaxis’s Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical development programs for the Company’s Lm Technology™ platform. Advaxis has initiated three new clinical trials in 2015, counting a combination study involving ADXS-PSA and Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). In addition, the Company anticipates to initiate six additional clinical trials by the end of year to evaluate its Lm Technology™ immunotherapy in cervical cancer, HPV-associated anal cancer and HER2 expressing solid tumors.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
